Last reviewed · How we verify
KL003 Cell Injection Drug Product
KL003 Cell Injection Drug Product is a Small molecule drug developed by Kanglin Biotechnology (Hangzhou) Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | KL003 Cell Injection Drug Product |
|---|---|
| Sponsor | Kanglin Biotechnology (Hangzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease (NA)
- Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia. (NA)
- Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients (NA)
- Β-Thalassemia Treatment with KL003 Cell Injection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KL003 Cell Injection Drug Product CI brief — competitive landscape report
- KL003 Cell Injection Drug Product updates RSS · CI watch RSS
- Kanglin Biotechnology (Hangzhou) Co., Ltd. portfolio CI
Frequently asked questions about KL003 Cell Injection Drug Product
What is KL003 Cell Injection Drug Product?
KL003 Cell Injection Drug Product is a Small molecule drug developed by Kanglin Biotechnology (Hangzhou) Co., Ltd..
Who makes KL003 Cell Injection Drug Product?
KL003 Cell Injection Drug Product is developed by Kanglin Biotechnology (Hangzhou) Co., Ltd. (see full Kanglin Biotechnology (Hangzhou) Co., Ltd. pipeline at /company/kanglin-biotechnology-hangzhou-co-ltd).
What development phase is KL003 Cell Injection Drug Product in?
KL003 Cell Injection Drug Product is in Phase 1.